Infectious Disease Diagnostics Testing Market Outlook 2025-2034: Market Share, and Growth Analysis By Type (Molecular Diagnostic Test, Point Of Care Tests (POCT) Infectious Disease Diagnostics Test), By Application (Respiratory, Human Immunodeficiency Vir

The Infectious Disease Diagnostics Testing Market is valued at USD 34.7 billion in 2025 and is projected to grow at a CAGR of 9.3% to reach USD 77.3 billion by 2034.The infectious disease diagnostics testing market involves laboratory and point-of-care tests used to detect pathogenic microorganisms including viruses, bacteria, fungi, and parasites. These diagnostics are essential for early detection, treatment planning, and containment of diseases such as influenza, HIV, tuberculosis, COVID-19, malaria, and hepatitis. The market encompasses molecular diagnostics (PCR, NAAT), immunoassays, rapid antigen tests, and culture-based methods. Increasing global disease burden, public health surveillance, and advances in diagnostic technologies continue to drive market growth. Additionally, rising antimicrobial resistance and the need for precise treatment protocols are fueling the demand for accurate, fast, and scalable testing solutions. The market was shaped by heightened demand for rapid testing platforms and molecular diagnostics. Post-pandemic vigilance led to widespread investment in laboratory infrastructure and mobile testing capabilities. Multiplex PCR panels gained adoption in hospitals for respiratory and gastrointestinal pathogens. Point-of-care tests saw expansion in low-resource settings, supported by global health initiatives. AI-based diagnostic software and digital readers were deployed for image-based interpretation of test results. Companies focused on automation to reduce turnaround times and labor dependency. Government agencies emphasized disease tracking and outbreak preparedness, boosting demand across diagnostic categories. The infectious disease testing will increasingly integrate with real-time epidemiological data systems and AI for predictive disease modeling. Portable genomic testing platforms will become more accessible, enabling early detection in community settings. At-home test kits will expand into more infectious disease categories, enhancing consumer accessibility and public health response. Cloud-based laboratory networks will support data sharing and outbreak alerts. Furthermore, advancements in CRISPR-based diagnostics and lab-on-a-chip technology will revolutionize field testing. As infectious threats evolve, diagnostics will play a pivotal role in early containment and precision care delivery.

Key Insights_ Infectious Disease Diagnostics Testing Market

Multiplex testing panels are being adopted for simultaneous detection of multiple pathogens in a single test run. AI-assisted diagnostic platforms are improving accuracy and interpretation of test results across varied settings. Point-of-care and at-home test kits are expanding access to infectious disease screening in remote regions. Cloud integration of diagnostic platforms is supporting real-time epidemiological monitoring and outbreak control. Next-generation sequencing (NGS) is being used for pathogen identification and surveillance of novel variants. Rising prevalence of infectious diseases and emerging outbreaks are fueling global testing demand across healthcare systems. Technological advancements in rapid, portable, and multiplex diagnostics are enhancing accessibility and efficiency. Government and NGO investments in healthcare infrastructure and pandemic preparedness are boosting market expansion. Growing antimicrobial resistance is necessitating precise diagnosis for targeted antibiotic treatment decisions. High costs of advanced molecular diagnostics may limit affordability and access in developing regions. Regulatory complexities and variability in test performance can hinder widespread adoption of newer diagnostic tools.

Infectious Disease Diagnostics Testing Market Segmentation

By Type

Molecular Diagnostic Test

Point Of Care Tests (POCT) Infectious Disease Diagnostics Test

By Application

Respiratory

Human Immunodeficiency Virus (HIV)

Healthcare-Associated Infections (HAIs)

Sexual Health

Tropical Diseases

Liver

By End-User

Diagnostic Laboratories

Hospitals And Clinics

Academic Research Institutes

Other End-Users

Key Companies Analysed

F. Hoffmann-La Roche Ltd.Thermo Fisher Scientific Inc.Abbott LaboratoriesDanaher CorporationSiemens Healthineers AGBecton Dickinson And CompanyQuest Diagnostics IncorporatedGrifols S.A.Hologic Inc.PerkinElmer Inc.bioMérieux SAQuidel CorporationSysmex CorporationBio-Rad Laboratories Inc.QIAGEN N.V.DiaSorin SpA (Luminex)Myriad Genetics Inc.Seegene Inc.Ortho Clinical Diagnostics Inc.OraSure Technologies Inc.Meridian Bioscience Inc.Trinity Biotech PLCBiodesix Inc.Helix OpCo LLCInovio Pharmaceuticals Inc.

Infectious Disease Diagnostics Testing Market Analytics

The report employs rigorous tools, including Porter’s Five Forces, value chain mapping, and scenario-based modeling, to assess supply–demand dynamics. Cross-sector influences from parent, derived, and substitute markets are evaluated to identify risks and opportunities. Trade and pricing analytics provide an up-to-date view of international flows, including leading exporters, importers, and regional price trends.

Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behavior are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.

Infectious Disease Diagnostics Testing Market Competitive Intelligence

The competitive landscape is mapped through OG Analysis’ proprietary frameworks, profiling leading companies with details on business models, product portfolios, financial performance, and strategic initiatives. Key developments such as mergers & acquisitions, technology collaborations, investment inflows, and regional expansions are analyzed for their competitive impact. The report also identifies emerging players and innovative startups contributing to market disruption.

Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across energy and industrial corridors.

Countries Covered

North America — Infectious Disease Diagnostics Testing market data and outlook to 2034

United States

Canada

Mexico

Europe — Infectious Disease Diagnostics Testing market data and outlook to 2034

Germany

United Kingdom

France

Italy

Spain

BeNeLux

Russia

Sweden

Asia-Pacific — Infectious Disease Diagnostics Testing market data and outlook to 2034

China

Japan

India

South Korea

Australia

Indonesia

Malaysia

Vietnam

Middle East and Africa — Infectious Disease Diagnostics Testing market data and outlook to 2034

Saudi Arabia

South Africa

Iran

UAE

Egypt

South and Central America — Infectious Disease Diagnostics Testing market data and outlook to 2034

Brazil

Argentina

Chile

Peru

Research Methodology

This study combines primary inputs from industry experts across the Infectious Disease Diagnostics Testing value chain with secondary data from associations, government publications, trade databases, and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation, and scenario planning, are applied to deliver reliable market sizing and forecasting.

Key Questions Addressed

What is the current and forecast market size of the Infectious Disease Diagnostics Testing industry at global, regional, and country levels?

Which types, applications, and technologies present the highest growth potential?

How are supply chains adapting to geopolitical and economic shocks?

What role do policy frameworks, trade flows, and sustainability targets play in shaping demand?

Who are the leading players, and how are their strategies evolving in the face of global uncertainty?

Which regional “hotspots” and customer segments will outpace the market, and what go-to-market and partnership models best support entry and expansion?

Where are the most investable opportunities—across technology roadmaps, sustainability-linked innovation, and M&A—and what is the best segment to invest over the next 3–5 years?

Your Key Takeaways from the Infectious Disease Diagnostics Testing Market Report

Global Infectious Disease Diagnostics Testing market size and growth projections (CAGR), 2024-2034

Impact of Russia-Ukraine, Israel-Palestine, and Hamas conflicts on Infectious Disease Diagnostics Testing trade, costs, and supply chains

Infectious Disease Diagnostics Testing market size, share, and outlook across 5 regions and 27 countries, 2023-2034

Infectious Disease Diagnostics Testing market size, CAGR, and market share of key products, applications, and end-user verticals, 2023-2034

Short- and long-term Infectious Disease Diagnostics Testing market trends, drivers, restraints, and opportunities

Porter’s Five Forces analysis, technological developments, and Infectious Disease Diagnostics Testing supply chain analysis

Infectious Disease Diagnostics Testing trade analysis, Infectious Disease Diagnostics Testing market price analysis, and Infectious Disease Diagnostics Testing supply/demand dynamics

Profiles of 5 leading companies—overview, key strategies, financials, and products

Latest Infectious Disease Diagnostics Testing market news and developments Show more